Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges

R.F. Kwekkeboom; Z. Lei; P.A.F.M. Doevendans; R.J. Musters; J.P.G. Sluijter

doi:10.1042/CS20140005

Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges

R.F. Kwekkeboom, Z. Lei, P.A.F.M. Doevendans, R.J. Musters, J.P.G. Sluijter

Research output: Contribution to journal › Literature review › peer-review

Abstract

Dysregulation of miRNA expression has been associated with many cardiovascular diseases in animal models, as well as in patients. In the present review, we summarize recent findings on the role of miRNAs in cardiovascular diseases and discuss the opportunities, possibilities and challenges of using miRNAs as future therapeutic targets. Furthermore, we focus on the different approaches that can be used to deliver these newly developed miRNA therapeutics to their sites of action. Since siRNAs are structurally homologous with the miRNA therapeutics, important lessons learned from siRNA delivery strategies are discussed that might be applicable to targeted delivery of miRNA therapeutics, thereby reducing costs and potential side effects, and improving efficacy.

Original language	English
Pages (from-to)	351-365
Number of pages	15
Journal	Clinical Science
Volume	127
Issue number	5-6
DOIs	https://doi.org/10.1042/CS20140005
Publication status	Published - Sept 2014

Keywords

antimiR
cardiovascular disease
miRNA
siRNA
targeted delivery method
CARDIOMYOCYTE PROGENITOR CELLS
CONTROLS CARDIAC-HYPERTROPHY
ISCHEMIA-REPERFUSION INJURY
SMALL-INTERFERING RNA
SIRNA DELIVERY
MICRORNA BIOGENESIS
IN-VIVO
MYOCARDIAL-INFARCTION
GENE DELIVERY
HEART-FAILURE

Access to Document

10.1042/CS20140005

http://www.ncbi.nlm.nih.gov/pubmed/24895056

Cite this

@article{b86d7c5c26dd40c28ae56de8c01185c2,

title = "Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges",

abstract = "Dysregulation of miRNA expression has been associated with many cardiovascular diseases in animal models, as well as in patients. In the present review, we summarize recent findings on the role of miRNAs in cardiovascular diseases and discuss the opportunities, possibilities and challenges of using miRNAs as future therapeutic targets. Furthermore, we focus on the different approaches that can be used to deliver these newly developed miRNA therapeutics to their sites of action. Since siRNAs are structurally homologous with the miRNA therapeutics, important lessons learned from siRNA delivery strategies are discussed that might be applicable to targeted delivery of miRNA therapeutics, thereby reducing costs and potential side effects, and improving efficacy.",

keywords = "antimiR, cardiovascular disease, miRNA, siRNA, targeted delivery method, CARDIOMYOCYTE PROGENITOR CELLS, CONTROLS CARDIAC-HYPERTROPHY, ISCHEMIA-REPERFUSION INJURY, SMALL-INTERFERING RNA, SIRNA DELIVERY, MICRORNA BIOGENESIS, IN-VIVO, MYOCARDIAL-INFARCTION, GENE DELIVERY, HEART-FAILURE",

author = "R.F. Kwekkeboom and Z. Lei and P.A.F.M. Doevendans and R.J. Musters and J.P.G. Sluijter",

year = "2014",

month = sep,

doi = "10.1042/CS20140005",

language = "English",

volume = "127",

pages = "351--365",

journal = "Clinical Science",

issn = "0143-5221",

publisher = "Portland Press Ltd.",

number = "5-6",

}

TY - JOUR

T1 - Targeted delivery of miRNA therapeutics for cardiovascular diseases

T2 - opportunities and challenges

AU - Kwekkeboom, R.F.

AU - Lei, Z.

AU - Doevendans, P.A.F.M.

AU - Musters, R.J.

AU - Sluijter, J.P.G.

PY - 2014/9

Y1 - 2014/9

N2 - Dysregulation of miRNA expression has been associated with many cardiovascular diseases in animal models, as well as in patients. In the present review, we summarize recent findings on the role of miRNAs in cardiovascular diseases and discuss the opportunities, possibilities and challenges of using miRNAs as future therapeutic targets. Furthermore, we focus on the different approaches that can be used to deliver these newly developed miRNA therapeutics to their sites of action. Since siRNAs are structurally homologous with the miRNA therapeutics, important lessons learned from siRNA delivery strategies are discussed that might be applicable to targeted delivery of miRNA therapeutics, thereby reducing costs and potential side effects, and improving efficacy.

AB - Dysregulation of miRNA expression has been associated with many cardiovascular diseases in animal models, as well as in patients. In the present review, we summarize recent findings on the role of miRNAs in cardiovascular diseases and discuss the opportunities, possibilities and challenges of using miRNAs as future therapeutic targets. Furthermore, we focus on the different approaches that can be used to deliver these newly developed miRNA therapeutics to their sites of action. Since siRNAs are structurally homologous with the miRNA therapeutics, important lessons learned from siRNA delivery strategies are discussed that might be applicable to targeted delivery of miRNA therapeutics, thereby reducing costs and potential side effects, and improving efficacy.

KW - antimiR

KW - cardiovascular disease

KW - miRNA

KW - siRNA

KW - targeted delivery method

KW - CARDIOMYOCYTE PROGENITOR CELLS

KW - CONTROLS CARDIAC-HYPERTROPHY

KW - ISCHEMIA-REPERFUSION INJURY

KW - SMALL-INTERFERING RNA

KW - SIRNA DELIVERY

KW - MICRORNA BIOGENESIS

KW - IN-VIVO

KW - MYOCARDIAL-INFARCTION

KW - GENE DELIVERY

KW - HEART-FAILURE

U2 - 10.1042/CS20140005

DO - 10.1042/CS20140005

M3 - Literature review

C2 - 24895056

SN - 0143-5221

VL - 127

SP - 351

EP - 365

JO - Clinical Science

JF - Clinical Science

IS - 5-6

ER -

Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges

Abstract

Keywords

Access to Document

Fingerprint

Cite this